Sinclair Pharma Share News (SPH)

Pharmaceuticals group Sinclair Pharma said it expects annual EBITDA to be in line with board expectations while revenue is expected to decline as wholesalers destock in the economic downturn. Revenues for the year ended 30 June 2009 are expected to be approximately £29.7m. Chief Executive Michael Flynn said, "These are challenging times for all companies and Sinclair is no exception. In the current economic environment we have seen the impact on our business of wholesalers reducing their stockholdings as a result of cash constraints. This has meant a one off reduction in salesFTSE TechMARK - RisersMorse (MOR) 30.00p +9.09%Phytopharm (PYM) 5.25p +7.58%Parity Group (PTY) 13.75p +3.77%Antisoma (ASM) 29.00p +3.57%Sepura (SEPU) 46.50p +3.33%Vernalis (VER) 81.25p +3.17%NCC Group (NCC) 359.00p +2.43%RM Group (RM.) 166.00p +1.84%KCOM Group (KCOM) 28.00p +1.82%Ricardo Group (RCDO) 208.00p +1.46%FTSE TechMARK - FallersSinclair Pharma (SPH) 23.50p -9.62%Oxford Biomedica (OXB) 10.50p -4.55%Skyepharma (SKP) 100.00p -4.53%GB Group (GBG) 21.50p -3.37%Biocompatibles International (BII) 179.25p -2.98%E2V Technologies (E2V) 57.00p -2.98%Filtronic (FTC) 35.50p -2.74%Wolfson Microelectronics (WLF) 103.75p -2.58%BATM Advanced (BVC) 39.00p -2.50%Indigo Vision (IND) 402.50p -1.83%